The DOI matches its Crossref record.
The Warfarin-Aspirin Symptomatic Intracranial Disease Study
Abstract
We conducted a retrospective, multicenter study to compare the efficacy of warfarin with aspirin for the prevention of major vascular events (ischemic stroke, myocardial infarction, or sudden death) in patients with symptomatic stenosis of a major intracranial artery.Patients with 50 to 99% stenosis of an intracranial artery (carotid; anterior, middle, or posterior cerebral; vertebral; or basilar) were identified by reviewing the results of consecutive angiograms performed at participating centers between 1985 and 1991. Only patients with TIA or stroke in the territory of the stenotic artery qualified for inclusion in the study. Patients were prescribed warfarin or aspirin according to local physician preference and were followed by chart review and personal or telephone interview. Seven centers enrolled 151 patients; 88 were treated with warfarin and 63 were treated with aspirin. Median follow-up was 14.7 months (warfarin group) and 19.3 months (aspirin group). Vascular risk factors and mean percent stenosis of the symptomatic artery were similar in the two groups, yet the rates of major vascular events were 18.1 per 100 patient-years of follow-up in the aspirin group (stroke rate, 10.4/100 patient-years; myocardial infarction or sudden death rate, 7.7/100 patient-years) compared with 8.4 per 100 patient-years of follow-up in the warfarin group (stroke rate, 3.6/100 patient-years; myocardial infarction or sudden death rate, 4.8/100 patient-years). Kaplan-Meier analysis showed a significantly higher percentage of patients free of major vascular events among patients treated with warfarin (p equals 0.01). The relative risk of a major vascular event in those treated with warfarin was 0.46 (95% CI, 0.23 to 0.86) compared with patients treated with aspirin. Major hemorrhagic complications occurred in three patients on warfarin (including two deaths) during 166 patient-years of follow-up and in none of the patients on aspirin during 143 patient-years of follow-up. This study suggests a favorable risk/benefit ratio for warfarin compared with aspirin for the prevention of major vascular events in patients with symptomatic intracranial large-artery stenosis. A prospective, randomized study is needed to confirm these findings. NEUROLOGY 1995;45: 1488-1493
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Savitz, S. I., & Caplan, L. R. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041544 · Cited by 485
Metadata
- Authors
- Chimowitz, M. I., Kokkinos, J., Strong, J., Brown, M. B., Levine, S. R., Silliman, S., Pessin, M. S., Weichel, E., Sila, C. A., Furlan, A. J., Kargman, D. E., Sacco, R. L., Wityk, R. J., Ford, G., Fayad, P. B., & for the Warfarin-Aspirin Symptomatic Intracranial Disease Study Group*
- Venue
- Neurology
- Published
- 1995-08
- Volume
- 45
- Issue
- 8
- Pages
- 1488-1493
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2092964229
- Cited by
- 621
- References
- 0
- FWCI
- 8.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Warfarin-Aspirin Symptomatic Intracranial Disease Study. https://app.cochat.ai/papers/10.1212/wnl.45.8.1488
- The paper
- Chimowitz, M. I., Kokkinos, J., Strong, J., Brown, M. B., Levine, S. R., Silliman, S., Pessin, M. S., Weichel, E., Sila, C. A., Furlan, A. J., Kargman, D. E., Sacco, R. L., Wityk, R. J., Ford, G., Fayad, P. B., & for the Warfarin-Aspirin Symptomatic Intracranial Disease Study Group*. (1995). The Warfarin-Aspirin Symptomatic Intracranial Disease Study. Neurology. https://doi.org/10.1212/wnl.45.8.1488
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
